Actively Recruiting

Phase 1
Age: 18Years +
FEMALE
ID06999798

A Phase 1 Study to Assess Safety and Ultrasound Visibility of an Optimized Twinkling Marker for Imaging Lymph Nodes in Clinically Node-Positive Breast Cancer

Led by Mayo Clinic ยท Updated on 2026-02-12

20

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

M

Mayo Clinic

Lead Sponsor

N

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating an optimized ultrasound twinkling marker to improve the imaging of lymph nodes in patients with clinically node-positive breast cancer. This phase 1 trial aims to assess the visibility and safety of this new marker, which is designed to enhance ultrasound detection compared to standard biopsy clip markers. The study focuses on patients who have biopsy-proven breast cancer involving lymph nodes and addresses the challenge of consistent marker visibility months after placement. Participants will undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node. Additional ultrasound imaging and standard mammography will be performed before starting neoadjuvant systemic therapy (NST). Optional ultrasound imaging during NST may be done if clinically needed. Surgery will then remove the twinkling marker along with the positive lymph node as part of standard care. Throughout the study, participants will have multiple imaging assessments evaluating the marker's visibility and any migration up to the surgery time, typically spanning 6 to 9 months. Safety will be monitored by tracking adverse events during this period. The main outcomes include how well the marker shows up on ultrasound and its position at surgery, helping to guide surgical removal of affected lymph nodes.

CONDITIONS

Brief Title

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
  • Surgical management planned by a designated breast surgeon
  • Ability to understand and comply with study procedures for the entire study duration
  • No contraception required during the study
Not Eligible

You will not qualify if you...

  • Pregnant patients
  • Current drug or alcohol use or dependence interfering with study adherence
  • Current or past participation in another clinical trial within a specified timeframe related to this intervention or treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Generally 6 to 9 months

Participants undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement. This is followed by additional ultrasound imaging and standard of care mammography prior to starting neoadjuvant systemic therapy (NST). Optional ultrasound imaging may occur during NST as clinically indicated.

Multiple imaging visits before and during NST as clinically indicated

Surgery and Immediate Post-operative Care

Duration - Up to the time of surgery

Participants undergo surgical removal of the optimized twinkling marker during standard of care surgical resection of the positive lymph node.

1 surgical visit (in-person)

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

B

Breast and Melanoma Surgical Oncology (BSMO) Clinical Research Unit

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Similar Trials

A Phase II Pilot Study of Lutetium (177Lu)-DOTATATE Treatmen...

Anatomic Stage IV Breast Cancer AJCC v8

Actively Recruiting

1 location

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone R...

Anatomic Stage 0 Breast Cancer AJCC v8

Actively Recruiting

1 location

[18F]FTT Positron Emission Tomography (PET) in Patients With...

Anatomic Stage IV Breast Cancer AJCC v8

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here